These findings indicate that integrating cancer vaccines into triple-combination regimens—comprising PI3K inhibitors, checkpoint inhibitors, and vaccines—could further enhance antitumor immunity by targeting multiple immunoregulatory pathways. The gene discussed is PIK3CA; the disease is cancer.